Clinical Trials Logo

ARID1A clinical trials

View clinical trials related to ARID1A.

Filter by:
  • None
  • Page 1

NCT ID: NCT04284202 Not yet recruiting - NSCLC Stage IV Clinical Trials

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evalute the efficacy and safety of PD-1 antibody combined with Dasatinib as third-line therapy for NSCLC patients with ARID1A mutation until disease progression or intolerable toxicity or patients withdrawal of consent. The target sample size is 30+individuals. The primary endpoint of this study is PFS、ORR、OS and the secondary endpoint is toxicity.